Stockscreener 앱 받기
9.41
5.33%
-0.53
Mink Therapeutics Inc 주식(INKT)의 최신 뉴스
Mink Therapeutics CEO Buell sells $73,265 in stock for tax obligations - Investing.com Nigeria
Form 4 Mink Therapeutics Inc: Jennifer Buell (Director, CEO) For: 11 October - Investing.com Nigeria
MiNK Therapeutics (INKT) CEO sells 6,938 shares solely to cover taxes owed upon vesting. - Stock Titan
Form 144 MiNK Therapeutics For: 13 October By Investing.com - Investing.com Nigeria
CEO lists 6,938 shares for sale at MiNK Therapeutics (Nasdaq: INKT) following stock award vesting. - Stock Titan
Agenus Inc. (AGEN) stock price, news, quote and history - Yahoo Finance Singapore
Orbit International Closes on New $6,000,000 Credit Facility; Also Completes $4,075,000 Private Placement - The Manila Times
A cell therapy enabled killing of immunotherapy-resistant colon cancer cells in a lab model - Stock Titan
MiNK Therapeutics’ agenT-797 Selected for ARPA-H BoSS Program to Advance Room-Temperature Cell Therapy Storage - Quiver Quantitative
Mink Therapeutics, Inc. Announces Selection of Clinical-Stage Agent-797 Inkt Platform for Arpa-H-Funded Initiative to Advance Room-Temperature Cell Therapy - marketscreener.com
Why (INKT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
MiNK Therapeutics (INKT) insider reports stock trades - Stock Titan
Insider at MiNK Therapeutics (NASDAQ: INKT) reports stock transactions - Stock Titan
Insider at MiNK Therapeutics (INKT) reports new stock trades - Stock Titan
Mink Therapeutics, Inc. (INKT) Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
MiNK Therapeutics (INKT) Drops 6.1% to $11.06 on Biotech Sector WeaknessWyckoff Distribution - vinanet.vn
MiNK (INKT) Results at a Glance: EPS Does Not Reach the Reported Estimate in the Reported Period; After Earnings: Shares Move Lower 3.11% in Latest TradingTech Earnings Analysis - vinanet.vn
MiNK Therapeutics Earnings Call Highlights ARDS Push - TipRanks
MiNK (INKT) Move: Finishes 4.99% Higher at $12.20 in the Current Update; Next Test: the $11.59 to $12.81 Range Remains in Focus in the Latest SessionCalendar Spread Trade - siam.in
MiNK (INKT) Move: Moves 0.15% Up to $11.37 for the Current Session; Price Setup: Support at $10.80 and Resistance at $11.94 Frame the Range at the CloseAI Trade Signals - vinanet.vn
MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript - AOL.ca
Q3 EPS Estimate for MiNK Therapeutics Boosted by Analyst - MarketBeat
MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript - Sahm
H.C. Wainwright Maintains MiNK Therapeutics(INKT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research - MarketBeat
MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript - AOL.com
MiNK Therapeutics (NASDAQ:INKT) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat
MiNK Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
MiNK Therapeutics (INKT) Slides 5.17% as Biotech Stock Tests Key Support at $10.45AAII Neutral - vinanet.vn
MiNK Therapeutics, Inc. (INKT) Presents at 2026 Military Health System Research SymposiumSlideshow - Seeking Alpha
MiNK Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
META_TITLE_QUOTE - Yahoo Finance
MiNK Therapeutics Q2 Earnings Call Highlights - MarketBeat
MiNK Therapeutics Q2 Earnings Call Highlights - TradingView
MiNK Therapeutics Q2 Results: Net loss narrows to $3.1M, cash at $8.8M - scanx.trade
INKT: Advanced phase II ARDS trial and global access for agenT-797, with stable financials - TradingView
MiNK Therapeutics (INKT.US) will release its earnings report after market close on August 13. - 富途牛牛
Earnings call transcript: MiNK Therapeutics narrows Q2 2026 loss as trial advances - Investing.com
Transcript : MiNK Therapeutics, Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com
INKT: Phase II trial for agenT-797 in ARDS shows early promise; global access and financial discipline maintained - TradingView
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury - Investing News Network
Form 8K Mink Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
MiNK Therapeutics reports Phase 2 trial data for agenT-797 By Investing.com - Investing.com Australia
MiNK Therapeutics reports Phase 2 trial data for agenT-797 By Investing.com - Investing.com South Africa
MiNK Therapeutics reports Phase 2 trial data for agenT-797 By Investing.com - Investing.com Nigeria
Form 8K Mink Therapeutics Inc For: 13 August By Investing.com - Investing.com India
Form 8K Mink Therapeutics Inc For: 13 August By Investing.com - Investing.com Canada
Form 8K Mink Therapeutics Inc For: 13 August By Investing.com - Investing.com UK
MiNK Therapeutics reports Phase 2 trial data for agenT-797 By Investing.com - Investing.com India
MiNK Therapeutics reports Phase 2 trial data for agenT-797 - Investing.com
4.22%
자본화:
|
볼륨(24시간):